Skip to main content

Table 1 Details of Studies with Control Groups

From: Intensive therapy and remissions in rheumatoid arthritis: a systematic review

First Author Study Year Design Groups RA Duration Quality Assessments Months Follow-up Treatments
       Allocation Blinding Bias Analysis   Control Intensive
Atsumi [28] C-Opera 2016 RCT 2 Early Low risk Low risk Low risk 12 MTX Certolizumab/MTX
Bakker [29] Camera II 2012 RCT 2 Early Low risk Low risk Low risk 24 MTX Prednisolone/MTX
Bijlsma [30] U-Act-Early 2016 RCT 3 Early Low risk Low risk Low risk 24 MTX Tocilizumab/MTX
Breedveld [31] Premier 2005 RCT 3 Early Low risk Low risk Low risk 24 MTX Adalimumab/MTX
Burmester [32] Function 2015 RCT 4 Early Unclear Unclear Low risk 12 MTX Tocilizumab/MTX
Capell [33] Mascot 2007 RCT 3 Est’lishd Low risk Low risk Low risk 12 MTX or SZP MTZ/SZP
Cohen [34] Reflex 2006 RCT 2 Est’lishd Low risk Low risk Low risk 6 MTX Rituximab/MTX
Detert [35] Hit Hard 2012 RCT 2 Early Low risk Low risk Low risk 6 MTX Adalimumab/MTX
Dougadas [36] Act-Ray 2013 RCT 2 Est’lishd Low risk Low risk Low risk 6 Tocilizumab Tocilizumab/MTX
Emery [37] Avert 2014 RCT 3 Early Low risk Low risk Low risk 12 MTX Abatacept/MTX
Emery [38] Comet 2008 RCT 2 Early Low risk Low risk Low risk 12 MTX Etanercept/MTX
Emery [39] Go Before 2009 RCT 4 Est’lishd Low risk Low risk Low risk 6 MTX Golimumab/MTX
Emery [40] Radiate 2008 RCT 3 Est’lishd Low risk Low risk Low risk 6 MTX Tocilizumab/MTX
Emery [41] Serene 2010 RCT 3 Est’lishd Low risk Low risk Low risk 12 MTX Rituximab/MTX
Emery [42] C-Early 2017 RCT 2 Early Low risk Low risk Low risk 12 MTX Certolizumab/MTX
Genovese [43] RA Beacon 2016 RCT 3 Est’lishd Low risk Low risk Low risk 6 DMARD Baracitinib/DMARDs
Genovese [44] Toward 2008 RCT 2 Est’lishd Low risk Low risk Low risk 6 DMARD Tocilizumab/DMARD
Goekoop Ruitermann [45] BeSt 2005 RCT 4 Early Low risk Low risk Low risk 12 DMARDs Infliximab/DMARDs or Combination DMARDs
Grigor [46] Ticora 2004 RCT 2 Est’lishd Low risk Low risk Low risk 18 Usual Care Combination DMARDs
Hetland [47] Cimestra 2006 RCT 2 Earlya Unclear Low risk Low risk 12 MTX MTX/Ciclosporin
Horslev Petersen [48] Opera 2014 RCT 2 Earlya Low risk Low risk Low risk 12 MTX Adalimumab/MTX
Kavanaugh [49] Optima 2013 RCT 2 Est’lishd Low risk Low risk Low risk 6 MTX Adalimumab/MTX
Kivitz [50] Brevacta 2014 RCT 2 Est’lishd Low risk Low risk Low risk 6 DMARD Tocilizumab/DMARD
Klareskog [51] Tempo 2004 RCT 3 Est’lishd Low risk Low risk Low risk 6 MTX Etanercept/MTX
Kremer [52] 2005 RCT 3 Est’lishd Low risk Low risk Low risk 12 MTX Abatacept/MTX
Kremer [53] Lithe 2011 RCT 3 Est’lishd Low risk Low risk Low risk 24 MTX Tocilizumab/MTX
Kremer [54] 2012 RCT 7 Est’lishd Low risk unclear Low risk 6 MTX Tofacitinib/MTX
Kremer [55] 2013 RCT 4 Est’lishd Low risk Low risk Low risk 6 DMARD Tofacitinib/DMARD
Nam [56] Empire 2014 RCT 2 Earlya Low risk Low risk Low risk 12 MTX Etanercept/MTX
Nam [57] Idea 2014 RCT 2 Early Low risk Low risk Low risk 18 MTX MTX/infliximab
Schiff [58] Attest 2007 RCT 3 Est’lishd Low risk Low risk Low risk 12 MTX Abatacept/MTX or Infliximab/MTX
Schipper [59] 2012 Quasi-Exp 2 Early High risk High risk Indeterminate 12 Usual care Tight controlb
Smolen [60] Certain 2014 RCT 2 Est’lishd Low risk Low risk Low risk 12 DMARD Certolizumab/DMARD
Smolen [61] Go After 2009 RCT 3 Est’lishd Low risk Low risk Low risk 6 DMARD Golimumab/DMARD
Smolen [62] Option 2008 RCT 3 Est’lishd Low risk Low risk Low risk 6 MTX Tocilizumab/MTX
Smolen [63] Rapid2 2008 RCT 4 Est’lishd Low risk Low risk Low risk 6 MTX Certolizumab/MTX
Soubrier [64] Guepard 2009 RCT 2 Earlya Low risk High risk Unclear 12 MTX Adalimumab/MTX
St. Clair [65] 2004 RCT 3 Early Low risk Low risk Low risk 12 MTX Infliximab/MTX
Symmons [66] Brosg 2006 RCT 2 Est’lishd High risk Low risk Low risk 36 Symptomic Combination DMARDs
Tak [67] Image 2010 RCT 3 Early Low risk Low risk Low risk 12 MTX Rituximab/MTX
Takeuchi [68] Hopeful-1 2014 RCT 2 Early Low risk Low risk Low risk 6 MTX Adalimumab/MTX
Taylor [69] RA Beam 2017 RCT 3 Est’lishd Low risk Low risk Low risk 6 MTX Baracitinib/MTX
or Adalimumab/MTX
van der Heijde [70] Oral Scan 2013 RCT 3 Est’lishd Low risk Low risk Low risk 6 MTX MTX/Tofacitinib
Van Ejik [71] Stream 2012 RCT 2 Early Uncertain Low risk Low risk 24 Usual care Intensive treatment
van Vollenhoven [72] Oral Standard 2012 RCT 4 Est’lishd Low risk Low risk Low risk 6 MTX Tofacitinib/MTX or Adalimumab/MTX
Verstappen [73] Camera 2007 Open label 2 Early High risk High risk Indeterminate 24 Usual care Combination DMARDs
Weinblatt [74] Go Further 2013 RCT 2 Est’lishd Low risk Low risk Low risk 6 MTX Golimumab/MTX
Westhovens [75] 2009 RCT 2 Early Low risk Low risk Low risk 12 MTX Abatacept/MTX
  1. a. These trials enrolled patients with disease durations no more than 6 months. b. In Schipper et al. study by 12 months 16% controls had combination DMARDs and 6% had TNF inhibitors; with intensive treatment 30% had combination DMARDs and 12% TNF inhibitors. The trial was classified as comparing combination DMARDs
  2. Abbreviations: RCT Randomised controlled trial, Est’lishd Established, MTX Methotrexate, SZP Sulfasalazine, DMARD Disease modifying anti-rheumatic drugs